RxMP Therapeutics
RxMP Therapeutics is dedicated to developing innovative therapies aimed at preventing and treating hemorrhage and excessive bleeding associated with trauma, surgery, or bleeding disorders. The company focuses on creating novel hemostatic agents that can effectively stop bleeding while minimizing the risk of unwanted clotting elsewhere in the body. Their lead product, RMP-402, has significant market potential and is backed by substantial funding to support its development.
Industries
N/A
Nr. of Employees
small (1-50)
RxMP Therapeutics is currently seeking investment
RxMP Therapeutics is seeking a investment in the range of
Patents
Composition comprising red cell-derived microparticles and method of treating excessive bleeding
2022-02-08 • US-11241457-B2
View Details
Composition comprising red cell-derived microparticles and method of treating excessive bleeding
2022-02-08 • US-11241457-B2
View DetailsProducts
Red blood cell-derived microparticle hemostatic agent
A biologic hemostatic agent composed of microparticles derived from donor red blood cells, manufactured via a scalable physical process and freeze-dried for long-term storage; intended for systemic administration to prevent or stop excessive bleeding in therapeutic or prophylactic settings.
Red blood cell-derived microparticle hemostatic agent
A biologic hemostatic agent composed of microparticles derived from donor red blood cells, manufactured via a scalable physical process and freeze-dried for long-term storage; intended for systemic administration to prevent or stop excessive bleeding in therapeutic or prophylactic settings.
Expertise Areas
- Hemostatic therapeutic development
- Blood-derived biologics manufacturing
- Lyophilized biologic formulation and storage
- Systemic parenteral hemostatic therapy
Key Technologies
- Red blood cell-derived microparticles
- Lyophilization (freeze-drying)
- Scalable physical manufacturing processes for blood products
- Systemic parenteral formulation
Key People
President and CEO, Director
CSO, Director
Director
Shawna Khouri, MBID
COO
President and CEO, Director
CSO, Director
Director
Shawna Khouri, MBID
COO
News & Updates
Dr. Rif Pamukcu CEO and Dr. Mike Davis provide shareholders an update on the current raise and outlook for 2024.
Dr. Rif Pamukcu CEO and Dr. Mike Davis provide shareholders an update on the current raise and outlook for 2024.